Qilu Pharmaceutical is a top 3 pharma company in China. We cover diverse therapeutic areas with a focus on oncology, cardiovascular and metabolic diseases, immunology, infectious diseases, and CNS diseases.

In the United States, Qilu has 34 approved ANDAs, 9 Tentatively Approved ANDA's, and a a pipeline of over 50 generic and biosimilar products in R&D.

Qilu is also developing an innovative pipeline of various biologic modalities (monoclonal/bispecific/trispecific antibodies, ADCs, fusion proteins) and small molecules for oncology, immunology, cardiovascular, and metabolic diseases from IND-enabling to late clinical stage. These assets are available for global or ex-China licensing.